OnyxPhoenix kirjoitti: Ti Marras 09, 2021 10:43 pm
Marokon Kauhu kirjoitti: Ti Marras 09, 2021 10:12 pm
OnyxPhoenix kirjoitti: Ti Marras 09, 2021 10:04 pmEi muuta yhtään mitään että COVID-19:sta liittyvä patenttihakemus jätettiin vasta 17.5.2020.
Niin no ei se mitään muutakaan, sikäli, että ei tuossa ollut alun perinkään mitään ihmeellistä.
Miksi siis postasit sen, ja mitä halusit postauksella sanoa?
No pitääkö se piirtää?
Nämä on tienneet tämän tulevan jo ajat sitten.
En kuulu ns. "koronanvastustajiin", mutta kyllä tämä on labrasta tullut, ja siinä on sekä jenkeillä että Kiinalla näppinsä pelissä.
Miksi? Ehkä se vielä selviää missä mokattiin, ja mikä oli alkuperäinen tarkoitus.
System and Method for Testing for COVID-19
Publication Number: US-2020279585-A1
Patent Family: US-2020279585-A1
Priority Date: 2015-10-13
Eli et siis ymmärtänyt mitään mitä jo sanottiin. Ei ole tiedetty että Covid tulee "ajat sitten", vaan Covid-19:sta liittyvä patenttihakemus on jätetty 17.5.2020.
Priority date liittyy patenttiperheeseen tai tiettyyn patentin ominaisuuteen. Miten se voi olla niin vaikeaa ymmärtää vaikka jo vähintään 4 kertaa selitetty?
Hauska käydä täälläkin välillä...
Niin mitäs se Dr. David Martin löysikään näistä patenteista? Eihän Martin ole näitä patentteja pyöritellyt kuin vaivaiset koko elämänsä ja hän varmasti tietää patenteista aikalailla kaiken ja miten kuviot toimii. Kaikki alla olevat patentit liittyvät
SARS-CoV-2. Ensimmäiset vuodesta 1999. Et noita linkkejä lue, niin copy & paste olkoon sallittua, mutta laitetaan se linkki kumminkin:
https://www.m-cam.com/wp-content/upload ... Review.pdf
Linkin takaalöytyy tämä:
The following data is being made publicly available for the
Commons by M·CAM International LLC based on a series of
reviews of patent literature derived from references found in:
A novel bat coronavirus reveals natural insertions at the S1/S2 2 cleavage site of the Spike
protein and a possible recombinant 3 origin of HCoV-19 4 Hong Zhou1,8, Xing Chen2,8, Tao
Hu1,8 , Juan Li1,8, Hao Song3 , Yanran Liu1 , Peihan Wang1 5 , Di Liu4 , Jing Yang5 , Edward
C. Holmes6 , Alice C. Hughes2,*, Yuhai Bi5,*, Weifeng Shi1,7,*
The Proximal Origin of SARS-CoV-2 Kristian G. Andersen1,2*, Andrew Rambaut3, W. Ian Lipkin4,
Edward C. Holmes5 & Robert F. Garry6,7
And sequences leading to the reporting of genomic epidemiology at
https://nextstrain.org/ncov
Polybasic cleavage site for SARS CoV with novel spike protein and ACE2 RBD
US9834595
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising
the same for the treatment of viral diseases Ablynx N.V.
5-Jun-08
29-Oct-15
5-Dec-17
US9193780
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising
the same for the treatment of viral diseases Ablynx N.V.
5-Jun-08
5-Jun-09
24-Nov-15
US20190077847 14-Mar-19
AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND
POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES Ablynx N.V.
5-Jun-08
17-Oct-17
14-Mar-19
US20160152693 2-Jun-16
AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND
POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES Ablynx N.V.
5-Jun-08
29-Oct-15
2-Jun-16
US10550174
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising
the same for the treatment of viral diseases Ablynx N.V.
5-Jun-08
17-Oct-17
4-Feb-20
US10407492
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising
the same for the treatment of viral diseases Ablynx N.V.
5-Jun-08
17-Oct-17
10-Sep-19
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
O-linked glycans and SARS CoV Spike Protein Data disclosures
Document
number Title Assignee name
Priority
date
File date
Issue
date
US9644180
Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC.
18-Nov-13
12-Jun-15
9-May-17
US8741311
Methods and compositions for immunization against virus Academia Sinica
27-Mar-09
26-Mar-10
3-Jun-14
US8735416
Antiviral therapies Technische Universitaet Carolo-
Wilhelmina zu Braunschweig
21-Sep-05
23-Apr-12
27-May-14
US7604960
Transient protein expression methods Crucell Holland B.V.
15-Apr-99
1-Jun-07
20-Oct-09
US20200046826 13-Feb-20
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS Academia Sinica
27-Mar-09
4-Jun-19
13-Feb-20
US20200040042 6-Feb-20
CHIMERIC MOLECULES AND USES THEREOF Not Available
30-Mar-17
29-Mar-18
6-Feb-20
US20200002674 2-Jan-20
ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE Not Available
18-Nov-13
16-Sep-19
2-Jan-20
US20190376034 12-Dec-19
PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES
THEREOF Not Available
18-Nov-13
23-Aug-19
12-Dec-19
US20190316091 17-Oct-19
ERYTHROID CELLS COMPRISING ARGINASE Not Available
18-Nov-13
30-May-19
17-Oct-19
US20190316090 17-Oct-19
ERYTHROID CELLS COMPRISING ARGININE DEIMINASE RUBIUS THERAPEUTICS, INC.
18-Nov-13
30-May-19
17-Oct-19
US20190316089 17-Oct-19
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
10-May-19
17-Oct-19
US20190309262 10-Oct-19
ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE Not Available
18-Nov-13
4-Jun-19
10-Oct-19
US20190309261 10-Oct-19
ERYTHROID CELLS COMPRISING LYSINE OXIDASE Not Available
18-Nov-13
4-Jun-19
10-Oct-19
US20190264177 29-Aug-19
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
10-May-19
29-Aug-19
US20190263934 29-Aug-19
FC VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED
HALF-LIFE Not Available
26-Jan-18
25-Jan-19
29-Aug-19
US20190144827 16-May-19
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES RUBIUS THERAPEUTICS, INC.
18-Nov-13
19-Nov-18
16-May-19
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
US20180265847 20-Sep-18
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
29-Mar-18
20-Sep-18
US20180216067 2-Aug-18
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
29-Mar-18
2-Aug-18
US20180208897 26-Jul-18
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
19-Mar-18
26-Jul-18
US20180187154 5-Jul-18
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
20-Feb-18
5-Jul-18
US20180187153 5-Jul-18
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
20-Feb-18
5-Jul-18
US20180135012 17-May-18
MEMBRANE-RECEIVER COMPLEX THERAPEUTICS Not Available
13-May-15
13-May-16
17-May-18
US20180030411 1-Feb-18
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
13-Oct-17
1-Feb-18
US20170369843 28-Dec-17
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
29-Mar-17
28-Dec-17
US20170174783 22-Jun-17
Single-Arm Monovalent Antibody Constructs and Uses Thereof Not Available
10-May-12
20-Oct-16
22-Jun-17
US20160257932 8-Sep-16
GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS
COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER
POLYPEPTIDE
Not Available
18-Nov-13
17-May-16
8-Sep-16
US20150335728 26-Nov-15
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS Academia Sinica
27-Mar-09
18-Feb-14
26-Nov-15
US20150306212 29-Oct-15
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
12-Jun-15
29-Oct-15
US20150297677 22-Oct-15
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY Children Medical Center Corporation
13-Dec-12
12-Dec-13
22-Oct-15
US20150182588 2-Jul-15
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available
18-Nov-13
23-Dec-14
2-Jul-15
US20150125449 7-May-15
Single-Arm Monovalent Antibody Constructs and Uses Thereof Not Available
10-May-12
8-May-13
7-May-15
US20140113923 24-Apr-14
NOVEL ANTIVIRAL THERAPIES Not Available
21-Sep-05
23-Apr-12
24-Apr-14
US20100247571 30-Sep-10
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS ACADEMIA SINICA
27-Mar-09
26-Mar-10
30-Sep-10
US20090042793 12-Feb-09
Novel Antiviral Therapies BALZARINI JAN
21-Sep-05
21-Sep-06
12-Feb-09
US20080113409 15-May-08
Transient protein expression methods HATEBOER GUUS
15-Apr-99
1-Jun-07
15-May-08
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
US10557119
Erythroid cells comprising phenylalanine ammonia lyase RUBIUS THERAPEUTICS, INC.
18-Nov-13
10-May-19
11-Feb-20
US10344263
Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC.
18-Nov-13
29-Mar-17
9-Jul-19
US10329531
Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC.
18-Nov-13
13-Oct-17
25-Jun-19
US10307475
Methods and compositions for immunization against virus Academia Sinica
27-Mar-09
18-Feb-14
4-Jun-19
US10301594
Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC
18-Nov-13
19-Nov-18
28-May-19
US10301593
Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC.
18-Nov-13
19-Mar-18
28-May-19
US10253296
Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC.
18-Nov-13
28-Nov-17
9-Apr-19
1
SARS-CoV research specifically on ACE2 binding
Document
number Title Assignee name
Priority
date
File date
Issue
date
US9415087
Compositions and methods for treating coronavirus infection Ludwig-Maximilians-Universitaet
Muenchen
11-Mar-14
8-May-15
16-Aug-16
US8541003
Vectors expressing SARS immunogens, compositions containing such
vectors or expression products thereof, methods and assays for making
and using
Protein Sciences Corporation
20-Jun-03
21-Jun-04
24-Sep-13
US7750123
Antibodies against SARS-CoV and methods of use thereof Dana Farber Cancer Institute, Inc.
25-Nov-03
24-Nov-04
6-Jul-10
US7728110
Antibodies to SARS coronavirus Amgen, Inc.
19-May-06
21-May-07
1-Jun-10
US7696330
Binding molecules against SARS-coronavirus and uses thereof Crucell Holland B.V.
22-Jul-03
20-Jan-06
13-Apr-10
US7687475
RNA interference in respiratory epithelial cells University of Iowa Research
Foundation
9-Jul-04
16-Oct-07
30-Mar-10
US7629443
Neutralizing monoclonal antibodies against severe acute respiratory
syndrome-associated coronavirus New York Blood Center, Inc.
2-Jun-04
8-Feb-06
8-Dec-09
US7604960
Transient protein expression methods Crucell Holland B.V.
15-Apr-99
1-Jun-07
20-Oct-09
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
US7491489
Synthetic peptide targeting critical sites on the SARS-associated
coronavirus spike protein responsible for viral infection and method of use
thereof
The University of Hong Knog
22-Nov-04
28-Oct-05
17-Feb-09
US7320857
Characterization of the earliest stages of the severe acute respiratory
syndrome (SARS) virus and uses thereof
Chinese National Human Genome
Center at Shanghai
9-Jul-04
9-Jul-04
22-Jan-08
US7297786
RNA interference in respiratory epitheial cells University of Iowa Research
Foundation
9-Jul-04
11-Jul-05
20-Nov-07
US7151163
Antiviral agents for the treatment, control and prevention of infections by
coronaviruses Sequoia Pharmaceuticals, Inc.
28-Apr-03
28-Apr-04
19-Dec-06
US20200079781 12-Mar-20
Substituted 2,4 diamino-quinoline as new medicament for fibrosis,
autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related
diseases
Not Available
5-Sep-18
1-Aug-19
12-Mar-20
US20200061185 27-Feb-20
PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE The Scripps Research Institute
25-Oct-16
25-Oct-17
27-Feb-20
US20200009244 9-Jan-20
NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS Not Available
13-Jun-18
13-Jun-19
9-Jan-20
US20190328865 31-Oct-19
IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION Not Available
28-Jul-14
17-Nov-17
31-Oct-19
US20190256579 22-Aug-19
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS,
ANTIBODIES, AND THEIR USE
The U.S.A., as represented by the
Secretary, Department of Health
and Human Services
24-Feb-15
3-May-19
22-Aug-19
US20190194299 27-Jun-19
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING
ANTIBODIES AND METHODS OF USE THEREOF Not Available
25-Apr-14
19-Nov-18
27-Jun-19
US20190192691 27-Jun-19
REGULATED BIOCIRCUIT SYSTEMS Not Available
11-Apr-16
11-Apr-17
27-Jun-19
US20180334480 22-Nov-18
CORONAVIRUSES EPITOPE-BASED VACCINES RAMOT AT TEL-AVIV UNIVERSITY
LTD.
17-Sep-15
15-Sep-16
22-Nov-18
US20180332885 22-Nov-18
REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME Not Available
11-May-05
25-May-18
22-Nov-18
US20180244756 30-Aug-18
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS,
ANTIBODIES, AND THEIR USE
The United States of America, as
Represented by the Secretary,
Dept. of Health and Human
Services
24-Feb-15
24-Feb-16
30-Aug-18
US20180230447 16-Aug-18
ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN
CONVERTING ENZYME 2 (ACE2) Northwestern University
24-Jan-17
24-Jan-18
16-Aug-18
US20180177860 28-Jun-18
VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT,
AND PREPARATION METHOD THEREFOR Not Available
11-Jun-15
7-Jun-16
28-Jun-18
US20170158752 8-Jun-17
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING
ANTIBODIES AND METHODS OF USE THEREOF Not Available
25-Apr-14
27-Apr-15
8-Jun-17
US20170055566 2-Mar-17
REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME Not Available
11-May-05
22-Aug-16
2-Mar-17
US20160376321 29-Dec-16
A NOVEL SARS IMMUNOGENIC COMPOSITION BAYLOR COLLEGE OF MEDICINE
26-Nov-13
21-Nov-14
29-Dec-16
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
US20160082074 24-Mar-16
COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS
INFECTION
LUDWIG-MAXIMILIANS-
UNIVERSITAET MUENCHEN
11-Mar-14
8-May-15
24-Mar-16
US20150297677 22-Oct-15
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY Children Medical Center Corporation
13-Dec-12
12-Dec-13
22-Oct-15
US20150275183 1-Oct-15
Human Betacoronavirus Lineage C and Identification of N-Terminal
Dipeptidyl Peptidase As Its Virus Receptor Not Available
23-Sep-12
23-Sep-13
1-Oct-15
US20150150878 4-Jun-15
Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites
In The Viruses' Glycoproteins Not Available
4-Apr-12
4-Apr-13
4-Jun-15
US20140174460 26-Jun-14
REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME VECTOR TOBACCO INC.
11-May-05
10-Dec-13
26-Jun-14
US20130216566 22-Aug-13
Vectors expressing SARS immunogens, compositions containing such
vectors or expression products thereof, methods and assays for making
and using
ADAMS DANIEL
20-Jun-03
21-Jun-04
22-Aug-13
US20130196903 1-Aug-13
Multimeric Inhibitors of Viral Fusion and Uses Thereof JV BIO SRL
11-Aug-10
11-Aug-11
1-Aug-13
US20100204286 12-Aug-10
METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF
CYTOTOXIC AGENTS BYRNES JOHN J
12-Feb-09
11-Feb-10
12-Aug-10
US20100172917 8-Jul-10
Binding molecules against SARS-coronavirus and uses thereof Crucell Holland B.V.
22-Jul-03
16-Nov-09
8-Jul-10
US20100150923 17-Jun-10
FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL
PROTEINS, THEIR PRODUCTION AND USES
Chinese Academy of Medical
Sciences, Institute of Basic Medical
Sciences
20-Jun-05
13-Jun-06
17-Jun-10
US20100092470 15-Apr-10
ANTIBODIES, ANALOGS AND USES THEREOF ICB International, Inc.
22-Sep-08
21-Sep-09
15-Apr-10
US20100047767 25-Feb-10
PATHOGEN BINDING ITI SCOTLAND LIMITED
5-Feb-07
4-Feb-08
25-Feb-10
US20100035848 11-Feb-10
THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT BARNES THOMAS MICHAEL
10-Mar-08
10-Mar-09
11-Feb-10
US20090304683 10-Dec-09
Soluble Fragments of The Sars-Cov Spike Glycoprotein DIMITROV DIMITER S
19-Jan-07
19-Jan-07
10-Dec-09
US20090186014 23-Jul-09
METHOD FOR TREATMENT OF PANCREATITIS Ore Pharmaceuticals Inc.
10-Oct-07
9-Oct-08
23-Jul-09
US20090130691 21-May-09
SCREENING PROTEINASE MODULATORS USING A CHIMERIC PROTEIN
AND SKI-I PROPROTEIN CONVERTASE SUBSTRATES AND INHIBITORS
Institut de Recherches Cliniques de
Montreal
16-Sep-05
14-Sep-06
21-May-09
US20090099259 16-Apr-09
Method for regulating gene expression ANTHONY JOSHUA
28-Feb-06
28-Feb-07
16-Apr-09
US20090098530 16-Apr-09
Cell Line For Producing Coronaviruses CRUCELL HOLLAND B.V.
22-Jul-05
21-Jul-06
16-Apr-09
US20090083865 26-Mar-09
Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof CHAN TEH-SHENG
11-Jan-06
11-Jan-07
26-Mar-09
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
US20080248043 9-Oct-08
Antibodies to SARS coronavirus Amgen Inc.
19-May-06
21-May-07
9-Oct-08
US20080234345 25-Sep-08
METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE
DIGESTIVE TRACT Gene Logic Inc.
8-Sep-06
7-Sep-07
25-Sep-08
US20080159962 3-Jul-08
Use of Inhibitors of the Renin-Angiotensin System for the Treatment of
Lung Injuries
IMBA-INSTITUTE FUR MOLEKULARE
BIOTECHNOLOGIE GMBH
19-May-05
19-May-06
3-Jul-08
US20080113409 15-May-08
Transient protein expression methods HATEBOER GUUS
15-Apr-99
1-Jun-07
15-May-08
US20080107650 8-May-08
METHOD FOR TREATING INFLAMMATORY DISEASES OF THE DIGESTIVE
TRACT Gene Logic Inc.
8-Sep-06
7-Sep-07
8-May-08
US20080044437 21-Feb-08
Encapsidation System for Production of Recombinant Virus-Like Particles CHEN QUN
2-Sep-04
1-Sep-05
21-Feb-08
US20070298498 27-Dec-07
Adenoviral Amplicon and Producer Cells for the Production of Replication-
Defective Adenoviral Vectors, Methods of Preparation and Use Thereof CATALUCCI DANIELE
2-Nov-04
27-Oct-05
27-Dec-07
US20070238681 11-Oct-07
MODULATION OF ACE2 EXPRESSION BENNETT C F
7-Nov-06
7-Dec-06
11-Oct-07
US20070203073 30-Aug-07
SARS and Ebola inhibitors and use thereof, and methods for their
discovery BATES PAUL
22-Jun-05
21-Jun-06
30-Aug-07
US20070185044 9-Aug-07
Modulation of ace2 expression BENNETT C F
8-Mar-05
8-Mar-05
9-Aug-07
US20070185027 9-Aug-07
ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION
OF INFECTIONS BY CORONAVIRUSES SEQUOIA PHARMACEUTICALS, INC.
28-Apr-03
9-Nov-06
9-Aug-07
US20070003577 4-Jan-07
Purified trimeric S protein as vaccine against severe acute respiratory
syndrome virus infections SUBBARAO KANTA
28-Jun-05
27-Jun-06
4-Jan-07
US20060258577 16-Nov-06
ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION
OF INFECTIONS BY CORONAVIRUSES ERICKSON JOHN W
28-Apr-03
28-Apr-04
16-Nov-06
US20060257852 16-Nov-06
Severe acute respiratory syndrome coronavirus Chiron Corporation
10-Apr-03
9-Apr-04
16-Nov-06
US20060240551 26-Oct-06
Neutralizing monoclonal antibodies against severe acute respiratory
syndrome-associated coronavirus HE YUXIAN
2-Jun-04
8-Feb-06
26-Oct-06
US20060240515 26-Oct-06
Soluble fragments of the SARS-CoV spike glycoprotein DIMITROV DIMITER S
21-Jul-03
19-Jan-06
26-Oct-06
US20060199176 7-Sep-06
Coronavirus S peptides CHONG PELE C S
15-Jul-04
14-Jul-05
7-Sep-06
US20060121580 8-Jun-06
Binding molecules against SARS-coronavirus and uses thereof CRUCELL
22-Jul-03
20-Jan-06
8-Jun-06
US20060110758 25-May-06
Synthetic peptide targeting critical sites on the SARS-associated
coronavirus spike protein responsible for viral infection and method of use
thereof
UNIV HONG KONG
22-Nov-04
28-Oct-05
25-May-06
ANIMATE VALUE™
[email protected] 513 E Main Street #2014 Charlottesville, VA 22902 T: 434· 979· 7240
US20060093616 4-May-06
Process for vaccinating eucaryotic hosts and for protecting against SARS-
CoV infection ALTMEYER RALF
29-Sep-04
28-Sep-05
4-May-06
US20050249739 10-Nov-05
Antibodies against SARS-CoV and methods of use thereof MARASCO WAYNE
25-Nov-03
24-Nov-04
10-Nov-05
US20050203038 15-Sep-05
Modulation of ACE2 expression
10-Mar-04
10-Mar-04
15-Sep-05
US20050113298 26-May-05
Receptor binding peptides derived from the SARS S protein
15-Sep-03
13-Sep-04
26-May-05
US20050112554 26-May-05
Characterization of the earliest stages of the severe acute respiratory
syndrome (SARS) virus and uses thereof HENG XU RUI
9-Jul-04
9-Jul-04
26-May-05
US10443049
Active low molecular weight variants of angiotensin converting enzyme 2
(ACE2) Northwestern University
24-Jan-17
24-Jan-18
15-Oct-19
US10301377
Middle east respiratory syndrome coronavirus immunogens, antibodies,
and their use
The United States of America, as
Represented by the Secretary,
Department of Health and Human
Services
24-Feb-15
24-Feb-16
28-May-19
US10131704
Middle east respiratory syndrome coronavirus neutralizing antibodies and
methods of use thereof
DANA-FARBER CANCER INSTITUTE,
INC.
25-Apr-14
27-Apr-15
20-Nov-18
-----------------------------------------------------
Dr. Martin kertoo näistä patenteista tarkasti miten tämä hommeli toimii: DR. DAVID MARTIN & REINER FUELLMICH INTERVIEW:
https://odysee.com/@vaccines-covid-nwo:3/JgxEMA02opvp:6
Ja loppuun vielä: Dr David Martin speech at the wise traditions conference:
https://odysee.com/@HumanitysVault:a/Dr ... nference:a
Tiedän, että et katso näitä Venäjän sponsoroimia linkkejä, sekä haastatteluja, analyyseja jne. En edes odota kommenttia näihin, koska selittelyn tulvaa joutuisi jo miettimään. Mukavaa patenttimaailmaan tutustumista.